Get Email Updates. Get CDCs free global health newsletter each week Enter your email address. The Philippines National Tuberculosis Program NTP ROSALIND G. VIANZON, MD, MPH Infectious Disease Prevention and Control Division DPCB, Department of Health, Manila. The tuberculosis profile of the Philippines, 20032011 advancing DOTS and beyond. National Tuberculosis Control Program. Manila, Department of Health, 2011. This Page is part of the Los Angeles County Public Health Home. Health Services, Tuberculosis Control Program, 2003. Philippines, 53. Factors Associated with Loss to Follow up during Treatment for Multidrug Resistant Tuberculosis, the Philippines, 2. Volume 2. 2, Number 3March 2. Emerging Infectious Disease journal. Thelma E. Tupasi , Anna Marie Celina G. Garfin, Ekaterina V. Kurbatova, Joan M. Microsoft Directshow 5 Cakewalk. Mangan, Ruth Orillaza Chi, Leilani C. Naval, Glenn I. Balane, Ramon Basilio, Alexander Golubkov, Evelyn S. Joson, Woo jin Lew, Vivian Lofranco, Mariquita Mantala, Stuart Pancho, and Jesus N. Sarol. Author affiliations Tropical Disease Foundation, Inc., Makati City, the Philippines T. E. Tupasi, L. C. Naval, G. I. Balane, E. S. Joson, J. N. Sarol Jr. Department of Health, Manila, the Philippines A. M. C. G. Garfin, R. Basilio Centers for Disease Control and Prevention, Atlanta, Georgia, USA E. V. Kurbatova, J. M. Mangan Philippine Business for Social ProgressInnovations and Multisectoral Partnership to Achieve Control of Tuberculosis Project, Manila R. Orillaza Chi US Agency for International Development USAID, Washington, DC, USA A. Tuberculosis In Africa' title='Tuberculosis In Africa' />Tuberculosis Control Program The National TB Control Program, organized in 1978. It also coordinates with the Philippine Health Insurance Corporation. National Tuberculosis Control Program. Philippines. National Tuberculosis Program NTP. A Successful Community Based Tuberculosis Control Program in Children in the Philippines Benjamin P. Java Projects With Source Code on this page. Sablan Jr., MD, MDM1, Josephine G. Aldaba, MD2, Florianne F. ENGAGING+THE+PRIVATE+SECTOR+IN+TB+CONTROL+IN+THE+CONTEXT+OF+AN+INVIGORATED+NATIONAL+TB+PROGRAM+%28NTP%29.jpg' alt='Tuberculosis In The Us' title='Tuberculosis In The Us' />Navy Tuberculosis ProgramGolubkov World Health Organization Philippines, Manila W. Lew The Lung Center of the Philippines, Manila V. Lofranco, S. Pancho Technical Assistance to the CountriesUSAID funded activity, Manila M. MantalaCite This Article. Abstract. To identify factors associated with loss to follow up during treatment for multidrug resistant MDR tuberculosis TB in the Philippines, we conducted a casecontrol study of adult patients who began receiving treatment for rifampin resistant TB during July 1December 3. Among 9. 1 case patients those lost to follow up and 1. Protective factors included receiving any type of assistance from the TB program, better TB knowledge, and higher levels of trust in and support from physicians and nurses. These results provide insights for designing interventions aimed at reducing patient loss to follow up during treatment for MDR TB. The Philippines is 1 of 2. TB 1, including multidrug resistant MDR TB resistant to isoniazid and rifampin 1. Compared with treatment for drug susceptible TB, treatment for MDR TB is longer, more expensive, and less effective, and it causes more medication side effects 25. Resistance to anti TB drugs has been detected in all regions of the Philippines an estimated 8,5. MDR TB cases occurred in 2. Programmatic Management of Drug resistant Tuberculosis PMDT was jointly initiated in the Philippines in October 2. Makati Medical Center in Metro Manila and the Tropical Disease Foundation, Inc., in collaboration with the National TB Control Program and the local government unit, as the first directly observed therapy DOTSplus pilot project for the management of MDR TB approved by the Green Light Committee 7. In 2. 00. 3, a grant proposal from the Philippines for Round 2 of the Global Fund to Fight AIDS, Tuberculosis and Malaria included treatment for 5. MDR TB National Tuberculosis Control Program, the Philippines, 2. Aug 2. 5Sep 6. Report of the Joint Program Review 2. Sep 3. 0, unpub. data. This funding was approved and subsequently expanded to 2,5. MDR TB patients approved to receive treatment according to a Round 5 proposal. In 2. 01. 0, a new coordination team for PMDT was established by the National TB Control ProgramDepartment of Health the Lung Center of the Philippines was the implementing arm for PMDT. As of September 2. PMDT health facilities were located in 1. The annual number of patients with drug resistant TB who began receiving treatment under PMDT increased from 1. Despite substantial progress made by PMDT in the Philippines, the proportion of patients for whom treatment was successful decreased from 7. Even with recent efforts to improve retention of patients receiving treatment for TB e. An effective approach to reducing loss to follow up during treatment for MDR TB is needed National Tuberculosis Control Program, the Philippines, 2. Aug 2. 5Sep 6. Report of the Joint Program Review 2. Sep 3. 0, unpub. data, especially in light of data from a prospective multinational study demonstrating that among MDR TB patients lost to follow up, almost a third had extensively drug resistant or preextensively drug resistant TB when treatment was started drug resistance was acquired during treatment by an additional 1. In addition, a third of those lost to follow up remained culture positive at last contact, enabling community transmission of strains with more extensive resistance 1. However, most studies of loss to follow up were done retrospectively, through medical record reviews 1. Specific reasons why patients in the Philippines are lost to follow up during MDR TB treatment are limited and based primarily on the views of healthcare providers. We aimed to determine which individual, diagnosis and treatment, interpersonal, healthcare setting, and social factors were significantly associated with patient loss to follow up during MDR TB treatment in the Philippines. Methods. Study Design and Patient Population. We conducted a casecontrol study among adult patients 1. MDR or rifampin resistant TB for whom treatment was initiated during July 1December 3. PMDT treatment facilities in the Philippines. We excluded from study inmates, children lt 1. The study was approved by the institutional review board of the Tropical Disease Foundation, Inc., the Lung Center of the PhilippinesEthics Review Committee, and the Ethics Research Committee of the Philippine Tuberculosis Society, Inc. The US Centers for Disease Control and Prevention CDC determined that CDC staff involvement did not constitute engagement in human subject research and that submission for CDC institutional review board review was not required. In the Philippines, the standardized treatment regimen for MDR TB is pyrazinamide, kanamycin, levofloxacin, prothionamide, and cycloserine the intensive phase lasts 6 months and the continuation phase an additional 1. For this study, case patients were defined as patients who were lost to follow up from MDR TB treatment i. Those who later returned after being considered lost to follow up at the time of interview were eligible for inclusion in the study as case patients. Control patients were defined as patients who had continued treatment for MDR TB for 1. Data collection and interviews were conducted from April 1. July 3. 1, 2. 01. MDR TB treatment for 1. Figure 1. Figure 1. Selection of participants for study of loss to follow up during treatment for multidrug resistant tuberculosis MDR TB in the Philippines, 2. Study exclusion criteria were incarceration, age lt 1. Case patients were identified by review of MDR TB registers. The number of patients who were lost to follow up per treatment facility was assessed centers with 3 patients with drug resistant TB who had been lost to follow up by January 1, 2. Field study staff attempted to find all eligible patients who were lost to follow up and invite them to participate in the study. Two control patients were randomly selected for each enrolled case patient from the same PMDT treatment facilities at which treatment was initiated for case patients. Of 9. 86 eligible patients, a total of 2. Figure 1. Figure 2. Figure 2. Social ecologic model used to identify factors influencing loss to follow up during treatment for multidrug resistant tuberculosis in the Philippines, 2. Boldface indicates data collected through patient interviews and medical record.